Company Announcement, GlobeNewswire, Pharmaceuticals, Press releases | Essential Pharma announces €900 million recapitalisation thr ...
Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street ...
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...
Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...
The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...
Charles Schwab Investment Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...
Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $23.11 which represents a decrease of $-2.96 or -11.35% from the prior close of $26.07. The stock opened at $26.15 and ...
Fmr LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 10.9% in the third quarter, ...
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...
GlobalData on MSN7d
Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment"Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment" was originally created and published by Clinical ...
Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback